Ⅲ期非小细胞肺癌同步放化疗与序贯放化疗的临床疗效对比  

Comparison of Clinical Efficacy of Concurrent Radiotherapy and Chemotherapy for Stage Ⅲ Non-small Cell Lung Cancer

作　　者：张艳喜[1] 芮晓艳[1] 范洪峰[1] 

机构地区：[1]安徽省滁州市第一人民医院,239001

出　　处：《实用癌症杂志》2018年第2期277-279,共3页The Practical Journal of Cancer

摘　　要：目的探讨同步放化疗与序贯放化疗治疗Ⅲ期非小细胞肺癌的临床价值。方法将Ⅲ期非小细胞肺癌患者96例据奇偶数原则随机分为同步放化疗组(实验组,n=48)和序贯放化疗组(对照组,n=48),对比2组患者临床治疗效果。结果实验组患者CR、PR以及总有效率分别为29.2%、47.9%和77.1%,显著高于对照组患者CR、PR以及总有效率(20.8%、39.6%和60.4%),差异具统计学意义(P<0.05)。实验组患者骨髓抑制发生率为47.9%,显著高于对照组39.6%,差异具统计学意义(P<0.05);其余不良反应发生率差异不具统计学意义(P>0.05)。治疗后2组患者血清CD44v6以及VEGF水平均较治疗前有所下降,组内比较差异具统计学意义(P<0.05),尤以观察组患者血清CD44v6以及VEGF水平下降显著,组间比较差异具统计学意义(P<0.05)。实验组患者治疗后1、2年生存率以及局控率分别为75.0%、62.5%和91.7%,对照组患者治疗后1、2年生存率以及局控率分别为56.3%、37.5%和81.3%,组间差异具统计学意义(P<0.05)。结论同步放化疗治疗Ⅲ期非小细胞肺癌总有效率高,患者术后生存率高,骨髓抑制发生率虽高,但总体临床效果肯定。Objective To analyze the clinical value of concurrent radiotherapy and chemotherapy in the treatment of stage m non-small cell lung cancer. Methods 96 patients with non-small cell lung cancer patients, according to the odd even number principle were divided into the synchronous radiotherapy and chemotherapy group （ experimental group, n = 48 ） and sequential radiotherapy and chemotherapy group （control group, n=48 ） , clinical treatment effect of the 2 groups were compared. Results CR, PR and the total effective rate of the experimental group were 29.2% ,47.9 % and 77.1%, which were significantly higher than the control group ,20.8% ,39.6% and 60.4% , there had statistical difference （ P 〈 0.05 ）. The incidence of bone marrow suppression in the experimental group was 47.9% ,which was significantly higher than that of the control group,39.6% , the difference was statistically significant （P 〈0.05 ） ; the other adverse reaction rates had no statistical difference（ P 〉0.05 ）. After treatment,2 groups of patients with serum CD44v6 and VEGF levels were decreased compared with before treatment, the difference was statistically significant （ P 〈 0.05 ）, especially in the observation group patients with the serum CD44v6 and VEGF levels decreased significantly, the difference between the 2 groups was statistically significant （ P 〈0. 05 ）. The 1 - ,2-year survival rates and local control rates of the experimental group were 75.0%, 62.5% and 91.7%, respectively, in the control group, the 1-, 2-year survival rates and local control rates were 56.3 %, 37.5 % and 81.3 %, respectively, and the difference was statistically significant between the 2 groups （ P 〈 0.05 ）. Conclusion Synchronous radiotherapy and chemotherapy for stage III non-small cell lung cancer has high total effective rate, high survival rate after operation, the incidence of bone marrow suppression is high, but the overall clinical effect is positive.

关 键 词：非小细胞肺癌 同步放化疗 序贯放化疗 

分 类 号：R734.2[医药卫生—肿瘤]